Gateways to Clinical Trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 25, Issue 10, 2003, Pages 831-855

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABETIMUS; ADALIMUMAB; ALEMTUZUMAB; ASTEMIZOLE; ATAZANAVIR; BOSENTAN; BOTULINUM TOXIN B; CASPOFUNGIN; CICLESONIDE; CILOMILAST; DESLORATADINE; DIFLOMOTECAN; DORIPENEM; DULOXETINE; EFALIZUMAB; ESTRADIOL; ETIRACETAM; GLUCAGON LIKE PEPTIDE 1; IMATINIB; IVABRADINE; LINEZOLID; MORPHINE; MOXIDECTIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TERFENADINE; TIPRANAVIR; UNINDEXED DRUG; XIMELAGATRAN; YM 337;

BLEEDING; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LIVER TOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY;

CLINICAL TRIALS; DRUG THERAPY; HUMANS;

EID: 1642471694     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (145)

1. Locatelli, F., Canaud, B., Giacardy, F., Martin-Malo, A., Baker, N., Wilson, J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003, 18(2): 362.
2. Smith, P.F. et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003, 14(5): 795.
3. Cortes, J.E., Ault, P., Koller, C. et al. Treatment of hypereosinophilic syndrome (HES) with imatinib mesylate. Blood 2002, 100 (11, Part 1): Abst 257.
4. Bussel, J.B., Hanna, K. Tolerability of rapid infusion administration of a novel IGIV preparation (IGVI-C, 10%) in patients with chronic idiopathic thrombocytopenic purpura (ITP). J Allergy Clin Immunol 2003, 111 (2, Part 2): Abst 632.
5. Tardif, J.-C., Ford, I., Tendera, M., Fox, K., Bourassa, M.G. Anti-anginal and anti-ischemic effects of the If current inhibitor ivabradine versus atenolol in stable angina. Circulation 2003, 108 (17, Suppl. 4): Abst 2687.
6. Camm, J., Lau, C.-P., Savelieva, I., Behr, E. Electrophysiological effects of the If current inhibitor ivabradine. Circulation 2003, 108 (17, Suppl. 4): Abst 1962.
7. 2A receptor agonist, binodenoson, compared to adenosine. Circulation 2003, 108 (17, Suppl. 4): Abst 1643.
8. 2A receptor agonist, binodenoson, and adenosine: A multicenter, randomized, dose-selection trial. Circulation 2003, 108 (17, Suppl. 4): Abst 2893.
9. 2A agonist: Results of a pilot study comparing adenosine with CVT-3146. Circulation 2003, 108 (17, Suppl. 4): Abst 2892.
10. Syeda, B., Kiss, K., Modarressy, K. et al. Assessment of safety and efficacy of the novel tetrapeptide (ITF-1697) on infarct size after primary PTCA in acute myocardial infarction: A randomized, placebo-controlled pilot trial. Circulation 2003, 108 (17, Suppl. 4): Abst 1931.
11. Touboul, P., Brugada, J., Capucci, A., Crijns, H.J.G.M., Edvardsson, N., Hohnloser, S.H. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003, 24(16): 1481.
12. McLaurin, B.T., San, G.W., Chen, C., Kosinski, E.J., Dillon, P.M., O'Dell, S.W. Intravenous selodenoson (formerly DTI0009), a novel adenosine A1 agonist, acutely controls ventricular rate in atrial fibrillation without significant hemodynamic consequences. Circulation 2003, 108 (17, Suppl. 4): Abst 2164.
13. Greenberg, B.H., Banish, D., Goldman, S. et al. BG9928, an oral adenosine antagonist, preserves renal function, improves sodium excretion and is well tolerated in heart failure patients. Circulation 2003, 108 (17, Suppl. 4): Abst 1602.
14. Kivikko, M., Lehtonen, L., Colucci, W.S. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003, 107(1): 81.
15. Sokos, G.G., Nikolaidis, L.A., Mankad, S. et al. Recombinant glucagon like peptide-1 (rGLP-1) improves clinical and functional performance in patients with advanced heart failure. Circulation 2003, 108 (17, Suppl. 4): Abst 1839.
16. Camm, A.J., Lau, C.P. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R&D 2003, 4(2): 83.
17. Khan, M., Lalwani, N.D., Drake, S.L., Crockatt, J.G., Dasseux, J.-L. Single-dose intravenous infusion of ETC-642, a 22-mer ApoA-1 analogue and phospholipids complex, elevated HDL-C in atherosclerosis patients. Circulation 2003, 108 (17, Suppl. 4): Abst 2570.
18. Estrach, C., Mpofu, S., Moots, R.J. Efficacy and safety of infliximab and adalimumab in Behcet's syndrome. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1125.
19. Al-Azzawi, F., Buckler, H.M. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric (Carnforth) 2003, 6(2): 118.
20. Lekakis, J.P., Papathanassiou, S., Papioannou, T.G. et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002, 86(2-3): 317.
21. Hiatt, W.R., Anthony, R., Koda, I. Benefit of NM-702, a phosphodiesterase inhibitor, in the treatment of claudication. Circulation 2003, 108 (17, Suppl. 4): Abst 2876.
22. Wigley, F.M., Wise, R., White, B. et al. Double-blind, placebo controlled, randomized, three period crossover, pilot study of single oral-28326 doses in scleroderma patients with Raynaud's phenomenon. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1138.
23. Duncan, G.E., Perkins, L.A., Theriaque, D.W., Neiberger, R.E., Stacpoole, P.W. Dichloroacetate improves submaximal exercise responses in patients with defects in mitochondrial energy metabolism. J Inherit Metab Dis 2003, 26 (Suppl. 2): Abst 220-P.
24. Mericq, V., Cassorla, F., Bowers, C.Y., Avila, A., Gonen, B., Merriam, G.R. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab 2003, 16(7): 981.
25. Babizhayev, M.A., Deyev, A.L. Yermakova, V.N. et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs R&D 2002, 3(2): 87.
26. Vazquez-Cobian, L.B., Flynn, T., Agle, L.M.A., Onel, K.B., Lehman, T.J.A. Treatment of resistant uveitis in children with adalimumab. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst SY24.
27. Sandborn, W.J., Sands, B.E., Wolf, D.C. et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: A randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003, 17(11): 1355.
28. Rutgeerts, P., Colombel, J., Enns, R. et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease therapy-1 (ENACT-1). 11th United Eur Gastroenterol Week (Nov 1, 2003, Madrid) 2003: Abst OP-G-297.
29. Johnson, D.A., Zuckerman, S., Levine, J.G. Impact of age on baseline severity of esophagitis and heartburn, and subsequent healing following treatment with esomeprazole or lansoprazole. Am J Gastroenterol 2002, 97 (9, Suppl.): Abst 43.
30. Fennerty, M.B., Zuckerman, S., Levine, J.G. The impact of duration of GERD symptoms on severity of esophagitis and response to treatment with esomeprazole or lansoprazole. Am J Gastroenterol 2002, 97 (9, Suppl.): Abst 57.
31. Armendariz-Borunda, J., Islas-Carbajal, M.C., Meza, E. et al. A pilot study of a novel anti-inflammatory and anti-fibrotic agent, pirfenidone, in patients with liver cirrhosis. 54th Annu Meet Am Assoc Study Liver Dis (Oct 24, 2003, Boston) 2003: Abst 314.
32. Wedemeyer, H. et al. Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis. 54th Annu Meet Am Assoc Study Liver Dis (Oct 24, 2003, Boston) 2003: Abst 294.
33. Reiser, M. et al. Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1. 54th Annu Meet Am Assoc Study Liver Dis (Oct 24, 2003, Boston) 2003: Abst 136.
34. Wise, S., Soon, D., Lowe, S. et al. Potent antiviral activity of LY582563 (MCC-478) in chronic hepatitis B infected patients. J Hepatol 2002, 36 (Suppl. 1): Abst 490.
35. Ishii, K., Takamura, N., Shinohara, M. et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. Hepatol Res 2003, 25(3): 226.
36. Mangia, A., Ricci, G.L., Minerva, N. et al. A randomised controlled trial on pegylated interferon alfa-2a (40KD) (Pegasys) or IFN alfa-2a (Roferon-A) plus ribavirin (RBV) and amantadine (AMA) vs IFN alfa-2a and RBV in naive patients with chronic HCV. J Hepatol 2003, 38 (Suppl. 2): Abst 528.
37. Okada, S., Tanaka, K., Sato, T. et al. Dose-response trial of lactoferrin in patients with chronic hepatitis C. Jpn J Cancer Res 2002, 93(9): 1063.
38. Gordon, S.C., Bacon, B.R., Jacobson, I.M. et al. Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks. 54th Annu Meet Am Assoc Study Liver Dis (Oct 24, 2003, Boston) 2003: Abst 312.
39. Boulet, L.-P., Canonica, G.W., Dahl, R. et al. Omalizumab, an anti-IgE antibody, provides parallel improvements in symptoms of allergic asthma and perennial allergic rhinitis in patients with both diseases: The SOLAR study. Chest 2003, 124 (4, Suppl.): 105S.
40. Berger, W.E., Schenkel, E.J., Mansfield, L.E. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol 2002, 89(5): 485.
41. Horizon, A., Weisman, M.H., Wallace, D.J. et al. Results of a randomized, placebo controlled, double blind phase 1/2 clinical trial (RCT) to assess the safety and tolerability of LJP 1082 in patients with antiphospholipid syndrome. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 884.
42. Diav-Citrin, O., Shechtman, S., Aharonovich, A. et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: A prospective controlled cohort study. J Allergy Clin Immunol 2003, 111(6): 1239.
43. Agbenyega, T., Planche, T., Bedu-Addo, G. et al. Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol 2003, 43(4): 386.
44. Kontoyiannis, D.P. et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003, 98(2): 292.
45. Barrios, A., Martín-Carbonero, L., Rios, P. et al. Efficacy and safety of atazanavir (ATV) in protease inhibitor-experienced HIV-infected patients. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 7.3/14.
46. Mukherjee, J., Wu, Y., Odeshoo, L. et al. Atazanavir (ATV) maintained patient utility and improved quality of life (QOL), comparing favorably to LPV/RTV: 24-Week data from BMS043. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 7.2/1.
47. Wu, Y., Odeshoo, L., Hoeje, U., Mukherjee, J., Cross, A., Giordano, M. Atazanavir (ATV) is associated with better patient adherence (AD): Long-term follow-up data from BMS 041 and 044 studies. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 10.1/15.
48. Hornberger, J., Youle, M., Beck, E.J., Maridalia, S., Green, J., Lewis, G. Cost-effectiveness of enfuvirtide from UK health payer perspective. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 19.5/1.
49. Walmsley, S., Clotet, B., Cooper, D. et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO trials. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 7.3/15.
50. Cohen, C. et al. Patient acceptance with self-injection of enfuvirtide (ENF) for HIV over 48 weeks of treatment. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 7.1/1.
51. Clumeck, N., Cohen, C.J., Thompston, M. et al. Impact of enfuvirtide on health-related quality of life at 48 weeks. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 7.3/19.
52. Neubacher, D., Markowitz, M., Slater, L., Curry, R., Mayers, D., McCallister, S. Long-term 80-week follow-up of highly treatment-experienced (HTE) patients on tipranavir-based antiretroviral therapy (BI 1182.2). 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 7.2/3.
53. Kohlbrenner, V., Gathe, J., Pierone, G. et al. Tipranavir/ritonavir (TPV/r) demonstrates potent efficacy in multiple protease inhibitor (PI)-experienced patients at 24 weeks: BI 1182.52. 9th Eur AIDS Conf (Oct 25, 2003, Warsaw) 2003: Abst 7.2/2.
54. Beale, R., Wright, T.J., Wong, K., Vincent, J.-L., Bernard, G. Safety of drotrecogin alfa (activated) in adult patients with severe sepsis: Comparison of global ENHANCE to PROWESS. Chest 2003, 124 (4, Suppl.): 102S.
55. Levy, M.M., Macias, W.L., Russell, J.A. et al. Failure to improve during first day of therapy is predictive of 28-day mortality in severe sepsis. Chest 2003, 124 (4, Suppl.): 120S.
56. Vincent, J.-L., Light, B., Wright, T., Wong, K., Johnson, G., Bernard, G. Global ENHANCE results indicate organ function improvement with drotrecogin alfa (activated) in severe sepsis patients. Chest 2003, 124 (4, Suppl.): 103S.
57. Wheeler, A.P., Doig, C., Wright, T., Wong, K., Vincent, J.-L., Bernard, G. Baseline characteristics and survival of adult severe sepsis patients treated with drotrecogin alfa (activated) in a global, single-arm, open-label trial (ENHANCE). Chest 2003, 124 (4, Suppl.): 91S.
58. Ely, E.W. et al. Drotrecogin alfa (Activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003, 37(2): 187.
59. Egan, J.M., Meneilly, G.S., Elahi, D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol - Endocrinol Metab 2003, 284(6): E1072.
60. Fineman, M.S., Biscak, T.A., Shen, L.Z. et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/ or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003, 26(8): 2370.
61. Kamatani, N., Fujimori, S., Hada, T. et al. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/ xanthine dehydrogenase inhibitor, for gout and hyperuricemia. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1349.
62. Davidson, M.H., McGarry, T., Bettis, R. et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002, 40(12): 2125.
63. Yokota, S., Miyamae, T., Imagawa, T. et al. Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1070.
64. Arnold, L.M., Lu, Y., Crofford, L.J. et al. A double-blind, multicenter trial comparing duloxetine to placebo in the treatment of fibromyalgia with or without major depressive disorder. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003, Abst 1810.
65. Wallace, D.J., Cardiel, M.H., Tumlin, J.A. et al. Safety results from a randomized controlled trial (RCT) of LJP 394 in systemic lupus erythematosus (SLE) patients with a history of renal disease. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1504.
66. Cardiel, M.H., Tumlin, J.A., Furie, R.A. et al. Clinical efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1503.
67. Strand, V., Aranow, C., Cardiel, M.H. et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003, 12(9): 677.
68. Furie, R., Stohl, W., Ginzler, E. et al. Safety, pharmacokinetic and pharmacodynamic results of a phase I single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 922.
69. Goupille, P., Girabeau, B., Conrozier, T., Marliere, J., Kiefer, P., Chevalier, X. Safety and efficacy of intra-articular injection of IL-1ra (IL-1 receptor antagonist) in patients with painful osteoarthritis of the knee: A multicenter, double blind study. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1822.
70. Bias, P., Buchner, A. Licofelone-an inhibitor of 5-LOX, COX-1 and COX-2-has superior GI tolerability in OA patients compared with naproxen, regardless of low-dose aspirin co-medication, previous ulcer history or H. pylori status. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 67.
71. Pavelka, K., Bias, P., Buchner, A., Lammerich, A., Schulz, U. Licofelone-a 5-LOX, COX-1 and COX-2 inhibitor-is as effective as celecoxib and shows better tolerability in patients with osteoarthritis of the knee. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 69.
72. Bias, P., Buchner, A. Licofelone-a 5-LOX, COX-1 and COX-2 inhibitor-is as effective as naproxen and has improved GI tolerability in patients with osteoarthritis. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 68.
73. Krege, J.H., Scheele, W.H., Xie, L., Genant, H.K. Teriparatide-induced reduction in the incidence of back pain persists at least 18 months after therapy discontinuation. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1124.
74. Schneider, M., Stahl, H.-D., Scaramucci, J., Vaishnaw, A., Podrebarac, T., Braun, J. Alefacept in subjects with active rheumatoid arthritis. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1709.
75. Maini, R.N., Taylor, P.C., Pavelka, K. et al. Efficacy of IL-6 receptor antagonist MRA in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1704.
76. Nishimoto, N., Yoshizaki, K., Miyasaka, N. et al. Long-term safety and efficacy of anti-interleukin 6 receptor antibody (MRA) in patients with rheumatoid arthritis. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 216.
77. Baslund, B., Tvede, N., Danneskiold-Samsoe, B. et al. A novel human monoclonal antibody against IL-15 (HuMax-IL15) in patients with active rheumatoid arthritis (RA): Results of a double-blind, placebo-controlled phase I/II trial. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1706.
78. Hawkey, C., Hoexter, G., Richard, D., Gitton, X., Weinstein, W. Lumiracoxib, a novel cyclooxygenase-2 selective inhibitor, has improved gastrointestinal safety and tolerability compared with non-selective nonsteroidal anti-inflammatory drugs: A pooled analysis. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 87.
79. Geusen, P., Alten, R., Rovensky, J. et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis: Results of a randomized double-blind study. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 544.
80. Toussirot, E., Robinet, E., Chabod, J. et al. Oral administration of E. coli bacterial extract (OM-89) in rheumatoid arthritis patients results in specific and nonspecific immunomodulation. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 765.
81. Sarzi-Puttini, P., Thomson, G., Sheldon, E. et al. Efficacy and safety of PEGylated recombinant methionyl human soluble tumor necrosis factor receptor type I: A phase 2 study in patients with rheumatoid arthritis. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 205.
82. Black, C.M., Korn, J.H., Mayes, M.D., Matucci-Cerinic, M. Improvements in the net ulcer burden and hand functionality in patients with digital ulcers related to systemic sclerosis. 67th Annu Meet Am Coll Rheumatol (Oct 23, 2003, Orlando) 2003: Abst 1137.
83. Barrou, B., Benoit, G., Ouldkaci, M. et al. A phase I/II vaccination study of patients with minimal residual prostatic adenocarcinoma after radical prostatectomy using autologous dendritic cells pulsed with recombinant PSA (Eladem™). Eur J Cancer 2002, 38 (Suppl. 7): Abst 453.
84. Gelderblom, H., Salazar, R., Verweij, J. et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 2003, 9(11): 4101.
85. Yamamoto, N., Tamura, T., Kamiya, Y. et al. Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors. Jpn J Clin Oncol 2003, 33(6): 302.
86. Kelly, W.K., Richon, V.M., O'Connor, O. et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9(10): 3578.
87. Thomas, M.B. et al. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/antiangiogenic agent given orally on a once-daily schedule for five days every three weeks in patients with solid tumors. Proc Am Assoc Cancer Res 2002, 43: Abst 2754.
88. Baselga, J., Llombart-Cussac, A., Bellet, M. et al. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol 2003, 14(9): 1383.
89. Holmes, F.A., O'Shaughnessy, J.A., Vukelja, S. et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002, 20(3): 727.
90. Body, J.J., Greipp, P., Coleman, R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003, 97 (3, Suppl.): 887.
91. Mohamed, I.E., Braun, D.P., Fanning, J. et al. A phase I/II pharmacokinetic and dose escalation study of H11 scFv (a human monoclonal antibody fragment). Breast Cancer Res Treat 2002, 76 (Suppl. 1): Abst 447.
92. Pusztai, L. et al. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 2003, 21(18): 3454.
93. Beerepoot, L.V., Witteveen, E.O., Groenewegen, G. et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: A pharmacokinetic and long-term safety study. Clin Cancer Res 2003, 9(11): 4025.
94. Spigel, S.C., Jones, S.F., Greco, F.A. et al. S-8184 vitamin E paclitaxel emulsion: Preclinical and phase I data. Proc Am Soc Clin Oncol 2002, 21 (Part 1): Abst 406.
95. Kris, M.G., Natale, R.B., Herbst, R.S. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA - J Am Med Assoc 2003, 290(16): 2149.
96. Hodi, F.S. et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003, 100(8): 4712.
97. Jeha, S., Steinherz, P., Altman, A. et al. A phase II, open-label study of Clofarex™ in pediatric patients with refractory or relapsed acute-myelogenous or lymphoblastic leukemia. Blood 2002, 100 (11, Part 2): Abst 4616.
98. Foran, J., Wetzler, M., Kantarjian, H.M. et al. A phase II, open-label study of Clofarex™ in adult patients with refractory or relapsed acute myelogenous leukemia. Blood 2002, 100 (11, Part 2): Abst 4613.
99. Hall, P.D., Moors, M., Cao, D., Frankel, A.E. Improving the therapeutic index of DT388-GMCSF, a fusion toxin for the treatment of acute myeloid leukemia (AML). Blood 2002, 100 (11, Part 2): Abst 4419.
100. Teo, R. et al. An open clinical evaluation of Permacol™ injection: A new urethral bulking agent. 33rd Annu Meet Int Continence Soc (Oct 5, 2003, Florence) 2003: Abst 600.
101. Lum, B.L., Srinivas, S., Beck, J.T. et al. Phase I study of oral gallium maltolate in patients with hematologic malignancies. Blood 2002, 100 (11, Part 2): Abst 4412.
102. Vose, J.M., Crump, M., Lazarus, H. et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003, 21(3): 514.
103. Bowen, C.P.R., Rovin, J.D., Thorne, K.B., Adams, R.B. Focal adhesion signaling in hepatocellular carcinoma (HCC): A mechanism of apoptosis. Dig Dis Week (May 17, 2003, Orlando) 2003: Abst T982.
104. Rifkin, R.M., Beveridge, R.A. Pegfilgrastim (pG-CSF) facilitates neutrophil engraftment in autologous peripheral blood stem cell transplantation (PBSCT). Blood 2002, 100 (11, Part 2): Abst 5474.
105. Ho, A.Y.L., El-Hemaidi, I., Kenyon, M., Pagliuca, A., Devereux, S., Mufti, G. Reduced-intensity allogeneic haematopoietic stem cell transplantation for poor prognosis myelodysplastic syndromes using fludarabine, busulphan and CAMPATH-IH (alemtuzumab) conditioning. Blood 2002, 100 (11, Part 1): Abst 2445.
106. Dressler, D., Benecke, R., Bigalke, H. Botulinum toxin type B (Neurobloc®) in patients with botulinum toxin type A antibody-induced therapy failure. Naunyn-Schmied Arch Pharmacol 2002, 365 (Suppl. 2): Abst 37.
107. Mula, M., Trimble, M.R., Liu, R., Sander, L. Levetiracetam and neuropsychiatric adverse events in patients with epilepsy. Epilepsia 2002, 43 (Suppl. 8): Abst 081.
108. Cramer, J.A., Follansbee, G., Vermilyea, J. Treatment persistence with new antiepileptic drugs: Levetiracetam, oxcarbazepine, topiramate, and zonisamide. Epilepsia 2002, 43 (Suppl. 7): Abst 2.256.
109. Palmer, O., Hattig, H., Bengner, T., Straub, H.B., Meencke, H.J. Cognitive effects of a levetiracetam add-on therapy in patients with pharmacoresistant focal epilepsies. Epilepsia 2002, 43 (Suppl. 8): Abst P557.
110. Martin, P., Guth, C. The use of levetiracetam (LEV) in adults with an intellectual disability and epilepsy. Epilepsia 2002, 43 (Suppl. 8): Abst P607.
111. Gilland, E., Ben-Menachem, E. Efficacy and tolerability of levetiracetam during one year follow-up in patients with refractory epilepsy. Epilepsia 2002, 43 (Suppl. 7): Abst 2.181.
112. Alsaadi, T.M., Thieman, C. Levetiracetam monotherapy for adults with epilepsy. Epilepsia 2002, 43 (Suppl. 7): Abst 2.253.
113. Bell, C. et al. The effects of levetiracetam on objective and subjective sleep parameters in healthy volunteers and patients with partial epilepsy. J Sleep Res 2002, 11(3): 255.
114. Soni, S., O'Rourke, M. Levetiracetam in learning disability adults with tonic-clonic seizures. Epilepsia 2002, 43 (Suppl. 8): Abst P606.
115. Pringsheim, T., Magnoux, E., Dobson, C.F., Hamel, E., Aube, M. Melatonin as adjunctive therapy in the prophylaxis of cluster headache: A pilot study. Headache 2002, 42(8): 787.
116. Leira, R., Dualde, E., Del Barrio, H., Machuca, M., Lopez-Gil, A. Almotriptan versus rizatriptan in patients with migraine in Spain. Headache 2003, 43(7): 734.
117. McCleane, G.J. A phase I study of the cholecystokinin (CCK) B antagonist L-365,260 in human subjects taking morphine for intractable non-cancer pain. Neurosci Lett 2002, 332(3): 210.
118. Czobor, P., Stark, J., Beer, G. et al. A double-blind, placebo controlled study of DOV273.547 (ocinaplon) in the treatment of generalized anxiety disorder (GAD). 33rd Annu Meet Soc Neurosci (Nov 8, 2003, New Orleans) 2003: Abst 959.12.
119. Check, J.H., Choe, J.K., Nazari, A., Davies, E., Kiefer, D. A prospective study to evaluate whether gonadotropin releasing hormone (GnRH) antagonists have an adverse effect on embryo implantation. Fertil Steril 2002, 78 (3, Suppl. 1): Abst P-188.
120. Schoolcraft, W., Surrey, E., Minjarez, D., Gardner, D.K. Antagonist/letrozole protocol for patients failing microdose agonist flare stimulation. Fertil Steril 2002, 78 (3, Suppl. 1): Abst P-358.
121. Ylikorkala, O., Cacciatore, B., Halonen, K. et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause (New York) 2003, 10(5): 440.
122. Ukena, D., Biberger, C., von Behren, V. et al. Ciclesonide significantly improves pulmonary function when compared with budesonide: A randomized 12-week study. Eur Respir J 2003, 22 (Suppl. 45): Abst 2640.
123. Sutherland, E.R., Martin, R.J., Ellison, M.C., Kraft, M. Immunomodulatory effects of melatonin in asthma. Am J Respir Crit Care Med 2002, 166(8): 1055.
124. Ferguson, G., Fischer, T.L., Morris, A., Zhu, J., Barnhart, F., Reisner, C. Cardiovascular safety of cilomilast in patients with chronic obstructive pulmonary disease (COPD). Chest 2003, 124 (4, Suppl.): 171S.
125. Fischer, T.L., Borker, R., Barnhart, F., Morris, A., Zhu, J. Effect of cilomilast on chronic obstructive pulmonary disease (COPD) patients with impaired quality of life (QOL). Chest 2003, 124 (4, Suppl.): 129S.
126. Borker, R.D., Morris, A., Lim, J., Zhu, J., Reisner, C. Effect of cilomilast on quality of life improvement/deterioration and non-drug costs in patients with chronic obstructive pulmonary disease. Chest 2003, 124 (4, Suppl.): 170S.
127. Moises, S., Girod, C.E., Shifren, A. et al. A double-blind, multicenter study comparing pirfenidone and prednisone for moderate-to-severe pulmonary fibrosis. Chest 2003, 124 (4, Suppl.): 116S.
128. Rosoph, L. Safety of efalizumab, a humanized monoclonal antibody, in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2003, 17 (Suppl. 3): Abst P27-60.
129. Ouellet, J.P., Toth, D., Gratton, D. Efalizumab provides rapid onset of clinical benefit in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2003, 17 (Suppl. 3): Abst P27-37.
130. Gilbert, M., Lynde, C.W. The benefits of continuous efalizumab therapy in patients with moderate to severe plaque-type psoriasis: Preliminary results from an open-label trial. J Eur Acad Dermatol Venereol 2003, 17 (Suppl. 3): Abst P27-58.
131. Carey, W., Gulliver, W.P. Efalizumab therapy improves and sustains health-related quality of life in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol 2003, 17 (Suppl. 3): Abst P27-38.
132. Cann, C., Curran, J., Milner, T., Ho, B. Unwanted effects of morphine-6-glucoronide and morphine. Anaesthesia 2002, 57(12): 1200.
133. Francis, C.W., Berkowitz, S.D., Comp, P.C. et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. New Engl J Med 2003, 349(18): 1703.
134. Kaufmann, S.S., Lyden, E.R., Brown, C.R. et al. Omeprozole therapy in pediatric patients after liver and intestinal transplantation. J Pediatr Gastroenterol Nutr 2002, 34(2): 194.
135. Graff, J., Klinkhardt, U., Westrup, D., Kirchmaier, C.M., Breddin, H.K., Harder, S. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans. Br J Clin Pharmacol 2003, 56(3): 321.
136. Clarke, J.G., Peipert, J.F., Hillier, S.L. et al. Microflora changes with the use of a vaginal microbicide. Sex Transm Dis 2002, 29(5): 288.
137. Thye, D.A., Kilfoil, T., Leighton, A., Wikler, M. Doripenem: A phase I study to evaluate safety, tolerability and pharmacokinetics in a Western healthy volunteer population. 43rd Intersci Conf Antimicrob Agents Chemother (Sept 14, 2003, Chicago) 2003: Abst A-21.
138. Derhaschnig, U., Reiter, R., Knöbl, P., Baumgartner, M., Keen, P., Jilma, B. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003, 102(6): 2093.
139. Wong, Y.N. et al. Safety, pharmacokinetics, and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol 2003, 43(7): 735.
140. Gajjar, D.A. et al. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003, 47(7): 2256.
141. Rordorf, C., Kellett, N., Mair, S. et al. Gastroduodenal tolerability of lumiracoxib vs. placebo and naproxen: A pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003, 18(5): 533.
142. Cotreau, M.M., Warren, S., Ryan, J.L. et al. The antiparasitic moxidectin: Safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 2003, 43(10): 1108.
143. Thomsen, M.S., Hansen, A.K., Olsen, U.F. et al. Effects of ReN1869, a CNS-available antihistamine, on capsaicin- and histamine-induced neurogenic inflammation in healthy subjects. Drug Dev Res 2002, 57(4): 193.
144. Hindmarch, I., Dawson, J., Stanley, N. Evaluation of the sleep-activity profile of pregabalin compared with alprazolam in normal volunteers. Sleep 2003, 26 (Suppl.): Abst 0211.C.
145. Ezrin, A., Grant, S., Bell, G. et al. Safety and pharmacokinetics of RSD1235, a novel atrial fibrillation converting drug, in healthy volunteers. Cardiovasc Drugs Ther 2002, 16 (Suppl. 1): Abst P297.